Advancing the prevention and treatment of HIV in children: priorities for research and development


Martina Penazzato, HIV Department, WHO, Geneva, Switzerland. Electronic address: penazzatom@who.int.
Claire L. Townsend, HIV Department, WHO, Geneva, Switzerland.
Nadia A. Sam-Agudu, Pediatric and Adolescent HIV Program and International Research Center of Excellence, Institute of Human Virology Nigeria, Abuja, Nigeria; Institute of Human Virology and Department of Pediatrics, University of Maryland School of Medicine, Baltimore, MD, USA.
Theodore D. Ruel, Department of Pediatrics, University of California San Francisco, San Francisco, CA, USA.
Moherndran Archary, Department of Paediatrics, University of KwaZulu-Natal, Durban, South Africa.
Adrie Bekker, Family Centre for Research with Ubuntu, Department of Paediatrics and Child Health, Stellenbosch University, Cape Town, South Africa.
Tim R. Cressey, AMS-IRD Research Collaboration, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand; Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK.
Angela Colbers, Department of Pharmacy, Radboud Institute for Health Sciences (RIHS), Radboud University Medical Center, Nijmegen, Netherlands.
Nandita Sugandhi, ICAP, Columbia University, New York, NY, USA.
Pablo Rojo, Pediatric Infectious Diseases Unit, Hospital 12 de Octubre, Madrid, Spain.
Natella Rakhmanina, School of Medicine and Health Sciences, The George Washington University, Washington, DC, USA; Children's National Hospital, Washington, DC, USA; Elizabeth Glaser Pediatric AIDS Foundation, Washington, DC, USA.
Melynda Watkins, Clinton Health Access Initiative, Boston, MA, USA.
Lisa Frigati, Department of Paediatrics, Stellenbosch University and Tygerberg Academic Hospital, Cape Town, South Africa.
Irene Mukui, Drugs for Neglected Diseases Initiative, Nairobi, Kenya.
Asma Hafiz, HIV Department, WHO, Geneva, Switzerland.
Marissa Vicari, International AIDS Society, Geneva, Switzerland.
Edmund V. Capparelli, Department of Pediatrics and Clinical Pharmacy, University of California San Diego, La Jolla, CA, USA.
Elaine J. Abrams, ICAP, Columbia University, New York, NY, USA; Department of Pediatrics, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA.

Document Type

Journal Article

Publication Date



The lancet. HIV




Safe and effective paediatric formulations of the most promising antiretroviral drugs are crucial to advance the treatment and prevention of HIV in neonates, infants, children, and adolescents. The WHO Paediatric Drug Optimization for HIV (PADO-HIV) group brings together stakeholders and experts every 2-3 years to identify priority products and define research gaps in the development of new HIV drugs and formulations for children in low-income and middle-income countries. PADO-HIV 5 met from Sept 27 to Oct 15, 2021. The group evaluated HIV agents from known and novel drug classes, oral and parenteral long-acting formulations, and developments in broadly neutralising antibodies, and included focused sessions on neonates and new delivery technologies. A list of medium-term and long-term priorities was generated, and research questions were defined. This forward-looking analysis is intended to provide guidance to funders, drug developers, and researchers, and to accelerate access for children to the best HIV drugs and formulations.